Investing.com -- Denmark’s export and investment fund EIFO and the Novo Nordisk (NYSE: NVO) Foundation are investing €80 million to establish QuNorth, a new Nordic quantum initiative that will ...

Novo Nordisk is still a dominant player in a growing industry, and it's still growing in the double-digits, even though it's now arguably priced more like a lower-growth consumer staples company.

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly inject ...

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

By Amina Niasse and Mariam Sunny (Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a study into a side effect of the jabs.

CleanSpark appears to be an attractive investment and the potential upside could be as high as 2x.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?

India Business News: Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 a ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the U.S. company is using 'deceptive marketing' to sell copycat versions of its obesity ...

Danish drugmaker Novo Nordisk has fast-tracked the India launch of its blockbuster anti-obesity drug Wegovy (semaglutide 2.4 mg), introducing the once-weekly injectable treatment at a starting ...